How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Draft guidance consultation

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about encorafenib plus binimetinib

Marketing authorisation indication

2.1

Encorafenib (Braftovi; Pierre Fabre Limited) plus binimetinib (Mektovi; Pierre Fabre Limited) is indicated for 'the treatment of adult patients with advanced non-small-cell lung cancer with a BRAF V600E mutation'.

Price

2.3

Encorafenib costs £1,400 for a 42‑pack of 75 mg capsules and binimetinib costs £2,240 per 84‑pack of 15 mg tablets (excluding VAT; BNF online accessed May 2025).

2.4

The company has a commercial arrangement for each drug. This makes encorafenib plus binimetinib available to the NHS with a discount and it would have also applied to this indication if encorafenib plus binimetinib had been recommended. The size of the discount is commercial in confidence.

Carbon Reduction Plan

2.5

Information on the Carbon Reduction Plan for UK carbon emissions for Pierre Fabre will be included here when guidance is published.